ArticlePharmaceuticals (Basel, Switzerland)2022

Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir.

Bandar Alosaimi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.